Efficiency of ultralow doses of antibodies to S100 protein and delta sleep-inducing peptide in rats with anxious depression.
Loskutova. L V LV; Shtark. M B MB; Epstein. O I OI
Key Findings
- A mixture of ultra‑low‑dose antibodies against S100 protein and DSIP reduced anxiety‑related behavior in several standard rat tests.
- Anti‑S100 antibodies alone also showed some anxiolytic effect, though weaker than the combination.
- The effects were observed after a single oral dose in rats subjected to acute stress.
Practical Outcomes
- The results suggest that ultra‑low‑dose antibodies might influence stress and mood pathways in animals, but the study does not provide a usable protocol for humans. Biohackers interested in DSIP should note that this work used antibodies, not the peptide itself, and was limited to rats, so no direct recommendations can be made for supplementation or dosing.
Summary
In a rat study, giving tiny oral doses of antibodies that target the S100 protein and the delta‑sleep‑inducing peptide (DSIP) helped reduce anxiety‑like behavior caused by a stressful shock. The combination of both antibodies worked best, while the anti‑S100 antibody alone showed a smaller benefit.
Abstract
We studied the effects of single peroral treatment with antibodies against S100 protein and delta sleep-inducing peptide in ultralow doses on behavioral characteristics of rats with anxious depression produced by acute stress (unavoidable electrical shock). Stress-produced behavioral changes and anxiolytic activity of antibodies were determined using the elevated plus-maze, open field, and tail suspension tests. High efficiency of the mixture of antibodies against S100 protein and delta sleep-inducing peptide was observed in all tests. Anxiolytic activity of anti-S100 antibodies (although less pronounced than that of the mixture of antibodies) was revealed in the elevated plus-maze and tail suspension test.
Study Information
pubmed
2003
10.1023/a:1024797722719